Cargando…

Association between NF-κB Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density

BACKGROUND: Osteoporosis is a systemic bone disease characterized by reduction of bone content. Bisphosphonates are first-line treatments for osteoporosis, but they have variable effectiveness. Genetic factors may explain these differences. The NF-κB signaling pathway plays a key role in the regulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Xiaoyi, Tan, Sasa, Feng, Xianzhen, Fu, Wenzhen, Hu, Yunqiu, Li, Miao, Wang, Wenjie, Yuan, Hu, Liu, Li, Wang, Chun, Hua, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970858/ https://www.ncbi.nlm.nih.gov/pubmed/35368772 http://dx.doi.org/10.1155/2022/2461716

Ejemplares similares

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density
por: Yuan, Hu, et al.
Publicado: (2023)

PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass
por: Zhao, Jiao, et al.
Publicado: (2021)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study
por: Grima, Daniel T, et al.
Publicado: (2010)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women
por: Berkhout, J, et al.
Publicado: (2016)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial
por: Yoon, Byung-Koo, et al.
Publicado: (2017)

Genetic Polymorphisms of Nuclear Factor-κB Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women
por: Wang, Wen-Jie, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Association between fibrinogen and bone mineral density in postmenopausal women
por: Du, Weibin, et al.
Publicado: (2023)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Association of chemerin levels and bone mineral density in Chinese obese postmenopausal women
por: Shi, Liang, et al.
Publicado: (2016)

Association of ADIPOR1 polymorphisms with bone mineral density in postmenopausal Korean women
por: Kim, Ha Young, et al.
Publicado: (2012)

Injectable alendronate-functionalized GelMA hydrogels for mineralization and osteogenesis
por: Liu, Lei, et al.
Publicado: (2018)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study
por: Yang, Dazhi, et al.
Publicado: (2023)

Association of Serum Periostin Level with Classical Bone Turnover Markers and Bone Mineral Density in Shanghai Chinese Postmenopausal Women with Osteoporosis
por: Li, Ran, et al.
Publicado: (2021)

Association between renal function and bone mineral density in healthy postmenopausal Chinese women
por: Li, Shuang, et al.
Publicado: (2019)

Polymorphisms in Genes Involved in the NF-κB Signalling Pathway Are Associated with Bone Mineral Density, Geometry and Turnover in Men
por: Roshandel, Delnaz, et al.
Publicado: (2011)

Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2005)

Association of the MTHFR C677T polymorphism and bone mineral density in postmenopausal women: a meta-analysis
por: Li, Donghua, et al.
Publicado: (2010)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Associations of Serum Cathepsin K and Polymorphisms in CTSK Gene With Bone Mineral Density and Bone Metabolism Markers in Postmenopausal Chinese Women
por: Gao, Li-hong, et al.
Publicado: (2020)

GIPR rs10423928 and bone mineral density in postmenopausal women in Shanghai
por: Zhang, Lizhi, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
por: Liao, Er-Yuan, et al.
Publicado: (2018)

The polymorphism of Insulin-like growth factor-I (IGF-I) is related to osteoporosis and bone mineral density in postmenopausal population
por: Yun-Kai, Li, et al.
Publicado: (2014)

Association between parity and bone mineral density in postmenopausal women
por: Yang, Yimei, et al.
Publicado: (2022)

Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis
por: Horst-Sikorska, Wanda, et al.
Publicado: (2012)

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors
por: Asaoka, Daisuke, et al.
Publicado: (2016)

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
por: Jensen, Paw, et al.
Publicado: (2022)

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women
por: Mobini, Maryam, et al.
Publicado: (2016)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

Association Analysis between g.18873C>T and g.27522G>A Genetic Polymorphisms of OPG and Bone Mineral Density in Chinese Postmenopausal Women
por: Wang, Fei, et al.
Publicado: (2014)

Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia
por: Liang, Ying, et al.
Publicado: (2016)

Non-association Between Polymorphisms of the Frizzled Receptor Genes and Bone Mineral Density in Postmenopausal Korean Women
por: Kim, Jung Gu, et al.
Publicado: (2009)

Polymorphisms of the human IL-1 receptor antagonist gene and forearm bone mineral density in postmenopausal women
por: Ivanova, Jivka T., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dbp1t0cte3do9r07f1pgtfqlnp